Personalis (NASDAQ:PSNL) Shares Up 6.8% – What’s Next?

Personalis, Inc. (NASDAQ:PSNL)’s stock price traded up 6.8% on Monday . The stock traded as high as $6.56 and last traded at $6.4310. 363,257 shares traded hands during trading, a decline of 75% from the average session volume of 1,436,175 shares. The stock had previously closed at $6.02.

Analysts Set New Price Targets

Several equities analysts have recently commented on the stock. Morgan Stanley lowered their target price on shares of Personalis from $11.00 to $10.00 and set an “equal weight” rating on the stock in a report on Thursday, March 5th. Needham & Company LLC boosted their target price on shares of Personalis from $10.00 to $12.00 and gave the stock a “buy” rating in a report on Friday, February 27th. Guggenheim boosted their target price on shares of Personalis from $12.00 to $13.00 and gave the stock a “buy” rating in a report on Monday, January 26th. Weiss Ratings reissued a “sell (d-)” rating on shares of Personalis in a report on Thursday, January 22nd. Finally, Wall Street Zen raised shares of Personalis from a “sell” rating to a “hold” rating in a research note on Sunday, March 8th. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $11.50.

Personalis Trading Up 6.1%

The firm has a market capitalization of $668.59 million, a PE ratio of -6.98 and a beta of 2.20. The business’s 50 day simple moving average is $7.73 and its 200 day simple moving average is $8.42.

Personalis (NASDAQ:PSNL) last issued its quarterly earnings data on Thursday, February 26th. The company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.05. Personalis had a negative net margin of 116.69% and a negative return on equity of 39.13%. The business had revenue of $17.35 million during the quarter, compared to analysts’ expectations of $17.12 million. Analysts forecast that Personalis, Inc. will post -1.4 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. T. Rowe Price Investment Management Inc. increased its position in Personalis by 273.9% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 10,780,290 shares of the company’s stock valued at $85,812,000 after acquiring an additional 7,896,714 shares during the last quarter. ARK Investment Management LLC increased its position in Personalis by 11.3% during the third quarter. ARK Investment Management LLC now owns 7,910,191 shares of the company’s stock valued at $51,574,000 after acquiring an additional 802,268 shares during the last quarter. AIGH Capital Management LLC increased its position in Personalis by 4.5% during the third quarter. AIGH Capital Management LLC now owns 3,892,101 shares of the company’s stock valued at $25,376,000 after acquiring an additional 168,143 shares during the last quarter. Aberdeen Group plc increased its position in Personalis by 36.1% during the fourth quarter. Aberdeen Group plc now owns 3,249,895 shares of the company’s stock valued at $25,869,000 after acquiring an additional 861,948 shares during the last quarter. Finally, Kennedy Capital Management LLC grew its holdings in shares of Personalis by 196.2% in the third quarter. Kennedy Capital Management LLC now owns 1,935,078 shares of the company’s stock worth $12,617,000 after purchasing an additional 1,281,695 shares during the last quarter. Institutional investors own 61.91% of the company’s stock.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical?stage genomics company that develops and markets advanced next?generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T?cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno?oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in?depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.